Healthcare & Life Sciences
Clinical & Commercial Insightin Days, Not Months.
AI-powered primary research with HCPs, KOLs, and patients — from concept testing through competitive landscape. Studies that used to take 3–6 months, delivered in 7–10 days.
Final ReportSpecialty Prescriber Treatment Decision Journey
What we do
Research across everyhealthcare vertical.
From concept testing through competitive landscape — one platform, one research team, one cost structure. Every engagement is strategist-led and delivered in 7–10 days. HoverTap any card to see the clinical impact.
01
Pharma
Brand strategy, prescriber insights, pricing
02
MedTech
Device prioritization, surgeon adoption, NPS
03
Diagnostics
Competitive positioning, clinical messaging
04
Life Science Tools
Buyer journey, technology adoption
Pharma
KOL & prescriber mapping
Map the real-world treatment decision journey — from patient presentation through therapy selection. Identify when physicians are most receptive and where field force engagement is misaligned.
Clinical Impact
Majority would switch patients
Unambiguous adoption signal across specialties. A majority of physicians would shift a portion of their monitoring volume to the expanded-lead patch — with a mean switching intent in the mid-50% range — driven by arrhythmia differentiation and ischemia evaluation that single-lead devices cannot perform.
MedTech
Concept & claims testing
Quantify feature value and product configuration strategy with MaxDiff, conjoint, and clinical use-case probes — directly from the surgeons and clinicians who will adopt.
Clinical Impact
Majority chose established doublet
Alternate-dose configuration meaningfully reduced discontinuation risk. Oncologists across multiple markets converged on the established doublet as the dominant IO backbone — and a majority preferred the alternate-dose configuration over standard.
Diagnostics
Competitive landscape
Where your platform actually wins and loses. Competitive perception rankings, positioning gaps, and the clinical evidence hierarchy that drives physician choice in your market.
Clinical Impact
Dominant incumbent share
Liquid biopsy is the growth lever — not new entrants. The market leader holds dominant adoption in both tissue and liquid biopsy workflows; the real volume shift is single tests moving to multiple serial draws per patient through expanded monitoring protocols.
Pharma
Pricing & value assessment
Van Westendorp, conjoint, and willingness-to-pay research with HCPs and payers. Quantify pricing headroom, packaging strategy, and the elasticity that drives formulary decisions.
Clinical Impact
~3× features over price
The lead clinical feature carried the largest share of purchase weight; device cost ranked last. In the affluent consumer segment, feature differentiation dwarfs pricing logic — a vast majority chose the premium tier.
Tools
Buyer journey & adoption
Map the complete purchase journey from trigger through selection. Stage-adaptive questioning captures real-time decision dynamics rather than retrospective recall — across multi-stakeholder buying committees.
Clinical Impact
Majority blocked on cost
Clinical urgency opens the door — financial proof closes the deal. Cost objections drive the majority of stakeholder pushback; the vast majority of buying processes take 6+ months end-to-end.
All Verticals
Patient & caregiver insights
Patient experience, treatment burden, unmet needs, and caregiver dynamics. Mixed-method research across patient populations — from rare disease to chronic conditions — that informs both clinical and commercial strategy.
Clinical Impact
Vast majority find CNS implant acceptable
Invasiveness isn’t the barrier — efficacy is.A vast majority of patients and caregivers accept a permanently implanted CNS delivery device, but only when it’s positioned as disease-modifying, not symptomatic.
Your research need isn't on this list?
Advisory boards, TPP optimization, message testing, payer access research, patient flow mapping, real-world evidence, and any custom methodology your team needs — all supported.
How it works
AI scale. Human judgment. Ten days.
AI handles the scale. Senior researchers steer the strategy.
- Day 0Kick-offAIDrafts the research brief from your key questionResearcherSenior researcher leads a 45-min intake call
- Day 1–2Design + recruitAIBuilds the guide and screener; sources verified clinicians, payers, KOLs from premium panelsResearcherReviews the study and vets the panel
- Day 3–5FieldAIRuns mixed-method interviews in parallelResearcherMonitors quality, flags and reruns
- Day 6–8AnalyzeAIRuns cross-tabs, thematic, sentiment, conjoint, MaxDiffResearcherValidates findings, builds the narrative
- Day 10ReportAIDrafts the decision-ready deck and workbookResearcherCurates the final, ships to your team
Selected work
Research that shaped
the commercial strategy.
Every engagement below delivered to an insights team in under two weeks. Methodology, sample, and clinical impact disclosed — client names held confidential.
Diagnostics
DiagnosticsN=65
Clinical Lab Capital Instrument Buyer Journey
Clinical urgency starts the conversation, finance controls every gate, coalition alignment closes the deal.
Life Science Tools
Life Science ToolsN=89
Next-Generation Molecular Profiling Method Adoption
Switching intent is high. The product specification is non-negotiable.
Diagnostics
DiagnosticsN=103
Clinical Cell Analysis Platform Segmentation
Three behavioral segments. One clear target. The firmographic model was wrong.
Pharma
Specialty PharmaN=37
Specialty Sterile Injectables Manufacturing Intelligence
API synthesis is the choke point. Raw-material geographic concentration is the systemic risk.
Digital Health
Digital HealthN=151
Performance Improvement Platform Validation
A vast majority see value. Buying group is collaborative, price lands within a well-defined band, timeline is 6 to 18 months.
MedTech
MedTechN=55
Expanded-Lead Cardiac Patch Adoption
A strong majority of physicians would move a portion of patients to the expanded-lead patch.
How it compares
One partner replacesthe research stack.
Most HCLS research runs through two vendor categories — full-service strategy consultancies and legacy CRO/market research firms. UserCue delivers what both promised — faster, with deeper clinical rigor, and at a fraction of the cost.
Research partner
AI-scaled, researcher-led primary research
Consulting
Strategy Consulting
LEK · ZS · McKinsey
Legacy MR / CRO
Traditional Research
Ipsos · Kantar · Research firms
Cost Per Engagement
Typical cost per study
A fraction of the cost
$150K–$350K+
$80K–$200K
Speed & Scale
Time to delivery
1–2 weeks
6–10 weeks
8–16 weeks
Typical sample size
50–1,500+
15–30 experts
40–100
Concurrent studies
Options depending on license
1
1
Methodology & Clinical Rigor
AI-moderated HCP interviews at scale
24/7, asynchronous
Not supported
!Limited pilots
Dedicated senior researcher with therapeutic expertise
No junior handoffs
Partner + team
!PM + analysts
Real-time QC during fielding
Live AI flags + clinical validation
Post-hoc
Post-hoc
Multi-country HCP/patient studies
Built-in, 40+ countries
!Via subcontractors
!Variable across countries
One conversation replaces a procurement cycle with two vendors.
UserCue is built for insights teams who need answers in days, not quarters. Fastest way to understand whether it fits your research cadence is a 30-minute briefing.
The research economics
A single multi-country HCP study costs
$100K–$350K+ and takes 3–6 months.
$100K–$350K+
Typical HCP research study
vs.
10×
More studies for the same budget
UserCue pricing is custom to your organization's research volume and scope. Every conversation starts with understanding your current research spend and decision cadence. Three ways to work with us:
First engagement
Pilot Study
$30K flat fee
One full-scale HCP or patient research study, end-to-end. Validate the fit with your insights team before committing to a broader engagement.
Study design, fielding, analysis, publication-ready report
Researcher-led with therapeutic area expertise
$30K flat fee + honoraria/CPI as pass-throughs · credited toward a license
For organization-wide deployment
Enterprise License
Unlimited on-demand research across brands, therapeutic areas, and geographies. One predictable structure — no per-project procurement.
Dedicated research leads with clinical expertise
All methodologies included — HCP, patient, payer, KOL
Full lifecycle: concept testing → launch → tracking → defense
Zero per-project fees
For variable research needs
Project Bundle
Pre-purchased research credits for teams not yet ready for a full license. No concurrency limits — flex across brands and therapeutic areas as needs arise.
Per-study rate scales with volume
12-month validity
All methodologies and researcher support included
Most of our partners start with a pilot study to validate fit with one active research need, then move to a license once their insights teams are live. Every conversation starts with understanding your organization — not selling a tier.
The depth of clinical insight was exceptional. What would have taken our team months to piece together from multiple vendors arrived in ten days — with the rigor we needed to present to our medical advisory board.
VP, Global Insights
Top-20 Pharma · Oncology Commercial Strategy
Ready to accelerate your
research timeline?
30 minutes. No pitch deck.We'll walk through a real deliverable from your therapeutic area and show you exactly how we'd approach your next study.
No commitment required. Pilot studies validate fit before any license conversation.